Threshold (THLD) at 5-Year High on Analyst PT Boost, Ahead of TH-302 Presentations
Tweet
Share
E-mail
Get Alerts THLD Hot Sheet
Join SI Premium – FREE
Threshold Pharmaceuticals (Nasdaq: THLD) now at a new 52-week high following a call by Lazard Capital earlier, doubling its price target in the process. Shares moved 10 percent higher to hit $8.77,otherwise known as the highest level they're been at since June 2007.
Lazard made the call ahead of the annual AACR meeting, which will host four presentations on Threshold's TH-302. For more on the Lazard call, click here.
Lazard made the call ahead of the annual AACR meeting, which will host four presentations on Threshold's TH-302. For more on the Lazard call, click here.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
